¥xÆW¤¤Âåºô¡B¥þ°ê³Ì¦h¤¤Âå®v§K¶OÂåÀø¿Ô¸ß¡B¤¤Âå¶E©Òºô¸ô±¾¸¹¤J¤f ¥xÆW¤¤Âåºô¡B¥þ°ê³Ì¦h¤¤Âå®v§K¶OÂåÀø¿Ô¸ß¡B¤¤Âå¶E©Òºô¸ô±¾¸¹¤J¤f
·j´M»¡©ú
95¤ÀÄÁ¦^ÂÐ
¡@1.²ßºD©Ê¸g´Á«eÀYµh,¥ªªÓ¡K

91¤ÀÄÁ¦^ÂÐ
¡@½Ð°Ý¦U¦ìÂå®v¤j¼w¡A¦³¤H»¡¡K

52¤ÀÄÁ¦^ÂÐ
¡@¦U¦ìÂå¥Í±z¦n¡A§Ú·Q½Ð±Ð±z¡K

15¤ÀÄÁ¦^ÂÐ
¡@½Ð°Ý¦U¦ìÂå®v¤j¼w¡A¥»¤H¦b¡K

87¤ÀÄÁ¦^ÂÐ
¡@½Ð°Ý¦U¦ìÂå®v¤j¼w¡A¤@¯ë¤H¡K

95¤ÀÄÁ¦^ÂÐ
¡@½Ð°Ý¦U¦ìÂå®v¤j¼w¡A¤@¯ë¤H¡K

榭G
1.²ßºD©Ê¸g´Á«eÀYµh,¥ªªÓ»Hµh 2.¸g±`©Ê«e¤@¦¸¤ë¸g¸ò¤U¤@¦¸¤ë¸g¤¤¶¡·|¡K
榭G
A.¥Ñ±z¥H¤Wªº­z»¡ ¢I¤@¯ë¤HºÎ¦bµw¦aªO¹ï¨­Åé¦n¶Ü¡H ¦]¤H²§ ¢I³q±`¡K
榭G
¦³¤H»¡°µ¤H­n¹³¤ô¡A°µ¨Æ­n¹³¤s A.¥Ñ±z¥H¤Wªº­z»¡ ¢I½Ð°Ý³o¼Ëªº·Qªk¥¿¡K
榭G
ªYªY ±z¦n ¦³©P¸£«Ç¥Õ½è³n¤Æ¬ÛÃö¯gª¬¡A°w¨b»P¤¤Ãİt¦X¶EÀø¡A´Nªñ±M·~¡K
榭G
¦U¦ìÂå¥Í±z¦n¡A§Ú·Q½Ð±Ð±z¡Aªñ¤é§Ú¥X²{¤ßŦÁôÁô§@µhªºª¬ªp¦ñÀHÀY·w¡A¦ý¡K
  

±MÄæ¤å³¹
¤ÀÃþ Á{§É¸gÅç
¼ÐÃD º©½Í¤Úª÷´Ë¤ó¯g(¥|)¦èÂåªvÀø
ÃöÁä¦r ¤Úª÷´Ë¤ó¯g/¦h¤ÚÓi/¤Úª÷´Ë¤ó¯f 
µoªí¤é´Á 2016-03-07
§@ªÌ µ{ºû¼w¤¤Âå®v 
ªA°È°|©Ò µ{ºû¼w¤¤Âå¶E©Ò 
¤å³¹¤º®e

º©½Í¤Úª÷´Ë¤ó¯g(¥|)¦èÂåªvÀø µ{ºû¼w¤¤Âå®v
¦èÂå¦bªvÀø­ìµo©Ê¤Úª÷´Ë¤ó¯g¥i°Ï¤À¬°ÃĪ«¡B¥~¬ì²`³¡¸£¨ë¿EDBS ©Î¿N¨`¥C¸£¤Î»a¥Õ²y¡B¸£¤º·F²Ó­M²¾´Ó¡B°ò¦]ªvÀø¡Bª«²zªvÀø©M¹B°Ê¡C
1. ÃĪ«Àøªk[1][2][3]¡G
a. ¥ª±Û¦h¤Ú-¥d¤ñ¦h¤Ú»s¾¯(Levodopa-Carbidopa)¡GLevodopa (¥ª±Û¦h¤Ú)³Ì¦³®Äªº¤Úª÷´Ë¤ó¯gªºÃĪ«¡A¶i¤J¤j¸£Âà¤Æ¦¨¬°¦h¤ÚÓi¡CÃĪ«¦pSinemet (¤ß¹ç¬ü)©ÎModopar (¬ü¹D´¶)¡C°Æ§@¥Î¦p­G¸z¤£¾A¡B¹Ã¤ß¡B¤ß¸õ¥[§Ö¡A°_¥ß©Ê§C¦åÀ£¯gª¬ªi°Ê¡A¶Ã°Ê¯g¡Aºë¯«¯f¯gª¬¡A¤Ûıµ¥¡C
b. ¦h¤ÚÓi¨üÅé¿E°Ê¾¯(Dopamine agonists)¡G¥i¥HÅý¥ª±Û¦h¤Ú§@¥Î«ùÄòªº®É¶¡§óªø¡A¤Î¥­·Æ¥¦±`¦³ªº¶}Ãö§@¥Î¡Cª½±µ¨ë¿E¤j¸£¤ºªº¦h¤ÚÓi±µ¨ü¾¹¡A¼W¥[¯«¸g°T¸¹ªº¶Ç°e¡C¦ppramipexole¼Ö§B§J¡Bropiniroleù¤Ç¥§Ã¹µ¥¡C¨ä°Æ§@¥Î¦p­G¸z¤£¾A¡A¹Ã¤ß¡A­¹¼¤¤£®¶¡A«K¯µ¡A¸¡Âm¡A­Â«å·P¡A°_¥ß©Ê§C¦åÀ£¡Cºë¯«¯f¯gª¬¡A¤Ûı¡A¥¢¯v¡B¶Ã°Ê¯g¡A«ü¦y³Â¥Ö½§¬õµh¡AªÍ³¡¤Î¸¡½¤«á³¡ÅÖºû¤Æµ¥¡C
c. B«¬³æÓi®ñ¤Æ–¡§í¨î¾¯(MAO-B inhibitors)¡G§í¨î¦h¤ÚÓiªº¸£¤º¥NÁ¡A¦pselegiline¤Ú¥i¡¡Brasagilineµ¥¡C¨ä°Æ§@¥Î¦p¹Ã¤ß¡A·NÃѲV¶Ã¡A¿E°Ê¡A¤Ûı¡A¼W±j¥ª¦h¤Ú¶Ã°Ê¯gµ¥¡C
d. ¨à¯ù×ôÓi¥Ò°òÂಾ–¡§í»s¾¯(Catechol O-methyltransferase (COMT) inhibitors¡^¡G³q¹LªýÂ_¤À¸Ñ¥ª±Û¦h¤Úªº–¡ªº§@¥Î¡A»´«×©µªø¥ª±Û¦h¤ÚªvÀø®É¶¡¡C¦³entacapone¿Õ±d°±¡Btolcaponeµ¥¡C°Æ§@¥Î¦p¼W±j¥ª¦h¤Úªº¶Ã°Ê¯g¡A¹Ã¤ß¡A°_¥ß©Ê§C¦åÀ£¡A¸¡Âmµ¥¡C
e. §Ü¤AñQÁxÆP¾¯(anticholinergics)¡G³Ì¦­ªvÀø¤Úª÷´Ë¤ó¯gªºÃĪ«¡A¥¦·|ªýÂZ¤AñQÁxÆPªº§@¥Î¡Aºû«ù¯¾ª¬Å餺¤AñQÁxÆP©M¦h¤ÚÓiªº¥­¿Å¡CArtane(¦w©Z)¡BBiperiden¤Úª÷¹çµ¥¡C°Æ§@¥Î¦p¤f°®¡Aµø¤O¼Ò½k¡A«K¯µ¡A±Æ§¿§xÃø¡AÀY©ü¡A­Â«å·P¡Aºë¯«¯gª¬µ¥¡C
f. ¦h¤ÚÓiÄÀ©ñ«P¶i¾¯¡GAmantadineªü°Ò¥L¿õ¬°§Ü¯f¬rÃĪ«¡AÁ{§É¤W¤×¨ä¬O§í¨î¥ª±Û¦h¤Ú¤Þ°_ªº²§°Ê¯g¡C°Æ§@¥Î¦p¤f°®¡Aµø¤O¼Ò½k¡A«K¯µ¡A±Æ§¿§xÃø¡Aºë¯«¯gª¬µ¥¡C
2. ¿N¨`¤Á¶}³N[4][5]¡G¥ßÅé©w¦V©ñ®gªvÀø¥Îγ-¤M©ÎX-¤M¿N¨`»a¥Õ²y¡Bµø¥C¡B¤Îµø¥C¤U®Öµ¥¡C¯}Ãa»a¥Õ²y°Ï¡A¯f±w´N¸û¤£·|ªÏÅ黸ª½¡C¯}Ãaµø¥C¡A¯f¤H´N¤£·|Ÿ§Ý¡C¯}Ãaµø¥C¤U®Ö¡A¯f±wªº©Ò¦³¯gª¬´N·|´î»´¡AÃĮĤ]·|¼W±j¡C
3. ¸£³¡²`¼h¨ë¿E³N(Deep Brain Stimulation¡ADBS) [4][5]¡G¸£³¡²`¼h¨ë¿E³N¬O¥Î¥ßÅé©w¦ì¤â³N¦b¿ï©wªº³¡¦ì´Ó¤J·PÀ³¹q·¥¡A³o¹q·¥¹q½u¦A³s±µ¨ì¯ß·i²£¥Í¾¹ (¯ß·i²£¥Í¾¹©M¤ßŦ¸`«ß¾¹Ãþ¦ü)¡A¥i¥H´Ó¤J ¯Ý³¡¥Ö½§¤U¡C¤º§t¦³¹q¦À©M·L¹q¤lºô¸ô¡A¥i¥H²£¥Í¹q¬y¨Ó¨ë¿E¯«¸g²Ó­M¥H§ïµ½¯gª¬¡C¨ë¿Eªº¶}Ãö¬O¥Ñ¯f¤H¨Ì¯fªp»Ý­n¡A¸g¥ÑºÏ©Ê±±¨î¾¹¨Ó¾ÞÁa¡C¯ÊÂI¬O¶O¥Î©ù¶Q¡A°·«O¥h¦~¶}©l¥i¥H¥Ó½Ðµ¹¥I¡A¸Ë§¹¤j·§¥i¥H´î¤Ö¤@¥bªºÃĪ«¶q¡C
4. ¸£¤º²Ó­M²¾´Ó[4][11]¡G¥i¤À­F­L·F²Ó­M¡B­F­L¸£²¾´Ó¡B°ö¾i·F²Ó­M²¾´Ó¡C¨ä¤¤¥H·F²Ó­M²¾´Ó¬°³Ì±`¥Î¡A­º¥ý¥ý°ö¾i·F²Ó­M¡AµM«á´Ó¤J¤j¸£¤¤¡A¥Î²¾´Óªº·F²Ó­M¤À¤Æ¦¨¶Â½è²Ó­M¨ú¥N±wªÌ¥¢¥hªº¶Â½è²Ó­M¡A­«·sªø¦^¶Â½è¯¾ª¬Åé¸ô®|¡A¨Ã¥B¤Àªc¦h¤ÚÓi§ïµ½À@Åé¥~¸ô®|ªº¹B°Ê»Ùê¡CÁ{§É¤HÅé¸ÕÅç¬ù¦b²¾´Ó«á3~6­Ó¤ë¡A¯gª¬·|³vº¥§ïµ½¡A¬ù¦Ü¤@¦Ü¤G¦~¥ª¥k¡A·|¹F¨ì³Ì¨ÎÀø®Ä¡A³o¬O¥Ø«e¦èÂå°ß¤@¥i¥H°±¤î¤Úª÷´Ë¤ó¯fªº¶iµ{¡A¬Æ¦Ü¦³°fÂà«ì´_¦Ü²¬Â¡ªº®ÄªG¡AÁ{§É¤W­Y¯à°t¦X¤¤ÃÄÀ³¸ÓÀø®Ä·|§ó¨Î¡A²Ó­M¦¨ªø¤À¤Æªº³t«×·|§ó§Ö¡C


°Ñ¦Ò¤åÄm
¤@¡B °Ñ¦Ò¤åÄm
[1].®]©É, ¶§¥ô¥Á, Áú´ºÄm¥D½s, ¹ê¥Î¤¤¦èÂåµ²¦X¯«¸g¯f¾Ç²Ä2ª©, ¤H¥Á½Ã¥Í¥Xª©ªÀ, 2011¦~: P707-736.
[2].Kurt J.Isselbacher, Eugene Braunwald, Jean D.Wilson, Joseph B.martin, Anthony S.Fauci, Dennis L.Kasper ¦XµÛ, Ĭ¯Â¼íĶ, «¢¨½°T¤º¬ì¾Ç¤â¥U²Ä¤Q¤Tª©, ¦X¬ö¹Ï®Ñ¥Xª©ªÀ, 2001¦~:736-741.
[3].¹ù²M¼ü, §õÂE´Ü, ¤Úª÷´Ë¤ó¯fªºÃĪ«ªvÀø, ÃľÇÂø»x¹q¤l³ø, 97´Á, 2009¦~.
[4].ªLªYºa, ¥xÆWÂå¾Ç, 1¨÷3´Á, 1997¦~:333-338.
[5].®}°¶¦¨, §õ¶W¸s, ªLªYºa, ¤Úª÷´Ë¤ó¯g¤§¥þ­±Æ[, ·OÀÙÅ@²zÂø»x, ²Äl¨÷²Ä3´Á, 2002¦~:8-16.


µ{ºû¼w¤¤Âå®v
µ{ºû¼w¤¤Âå¶E©Ò°|ªø
¤¤¦èµ²¦X¯«¸gÂå¾Ç·|ºÊ¨Æ
¤¤¦èµ²¦X¯«¸gÂå¾Ç·|½Òµ{Á¿®v
¶E©Ò¹q¸Ü02-29598113
 

·PÁ ·PÁµ{ºû¼w¤¤Âå®v§ë½Z¥»ºô¯¸¡AÂà¸ü½Ð¨ú±o­ì§@ªÌ¦P·N¡C
ÂI¾\¼Æ 7341

   ¨ä¥¦¬ÛÃö¥DÃDªº¤å³¹¡G
   ¨ä¥¦ÁÙ¦³¬ÛÃö¥DÃDªº¤å³¹29½g




¡u¥»ºô©Ò´£¨Ñªº°·±d¿Ô¸ß¡AµLªk¨ú¥NÂå®v¤§·í­±¶EÂ_¡A¥çµLªk´£¨ÑÂåÀø¦æ¬°¡A­Y¹J¯e¯f¤´½Ð¾¨³t´NÂå¡v
¥»ºô¯¸´£¨Ñ°·±dª¾ÃѸê°T¡A¸T¤î¥ô¦óºô»Úºô¸ôªA°È·~ªÌÂà¿ýºô¯¸¸ê°T¤º®e

¢x

¢x
¢x
¢x
¢x
¢x
¢x
¢x
¡@Copyright © 5151½u¤W°·±d·ÓÅ@Áp·ù    ¡u¤u¬ã°|¤å¦rÂà»y­µ¸Õ¥ÎªA°È²£¥X¤§¦X¦¨»y­µ¡v¡@ªA°È«H½c: ¼g«Hµ¹§Ú­Ì¡@